RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia
Open Access
- 24 September 2009
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 114 (13), 2744-2752
- https://doi.org/10.1182/blood-2008-09-179812
Abstract
RUNX1 (AML1) encodes the core binding factor α subunit of a heterodimeric transcription factor complex which plays critical roles in normal hematopoiesis. Translocations or down-regulation of RUNX1 have been linked to favorable clinical outcomes in acute leukemias, suggesting that RUNX1 may also play critical roles in chemotherapy responses in acute leukemias; however, the molecular mechanisms remain unclear. The median level of RUNX1b transcripts in Down syndrome (DS) children with acute megakaryocytic leukemia (AMkL) were 4.4-fold (P < .001) lower than that in non-DS AMkL cases. Short hairpin RNA knockdown of RUNX1 in a non-DS AMkL cell line, Meg-01, resulted in significantly increased sensitivity to cytosine arabinoside, accompanied by significantly decreased expression of PIK3CD, which encodes the δ catalytic subunit of the survival kinase, phosphoinositide 3 (PI3)–kinase. Transcriptional regulation of PIK3CD by RUNX1 was further confirmed by chromatin immunoprecipitation and promoter reporter gene assays. Further, a PI3-kinase inhibitor, LY294002, and cytosine arabinoside synergized in antileukemia effects on Meg-01 and primary pediatric AMkL cells. Our results suggest that RUNX1 may play a critical role in chemotherapy response in AMkL by regulating the PI3-kinase/Akt pathway. Thus, the treatment of AMkL may be improved by integrating PI3-kinase or Akt inhibitors into the chemotherapy of this disease.Keywords
This publication has 53 references indexed in Scilit:
- Identification and characterization of novel AML1-ETO fusion transcripts in pediatric t(8;21) acute myeloid leukemia: a report from the Children's Oncology GroupOncogene, 2008
- The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapyLeukemia, 2007
- Prognostic Factors and Risk-Based Therapy in Pediatric Acute Myeloid LeukemiaThe Oncologist, 2007
- Prognostic factors and outcome of recurrence in childhood acute myeloid leukemiaCancer, 2006
- Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination StudiesPharmacological Reviews, 2006
- Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer CenterBlood, 2006
- Acute megakaryoblastic leukemia in children and adolescents, excluding Down's syndrome: improved outcome with intensified induction treatmentLeukemia, 2005
- Transcriptional regulation of the cystathionine-β-synthase gene in Down syndrome and non–Down syndrome megakaryocytic leukemia cell linesBlood, 2003
- Acute megakaryoblastic leukemia: experience of GIMEMA trialsLeukemia, 2002
- Repression of Human Reduced Folate Carrier Gene Expression by Wild Type p53Published by Elsevier BV ,2001